MCID: STR020
MIFTS: 56

Strabismus

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Strabismus

MalaCards integrated aliases for Strabismus:

Name: Strabismus 57 12 76 29 55 6 44 15 73
Strabismus, Susceptibility to, 1 57 13
Strabismus, Susceptibility to 57
Susceptibility to Strabismus 29
Strabismus 1 57

Characteristics:

OMIM:

57
Inheritance:
familial, but no simple mendelian inheritance established


Classifications:



External Ids:

OMIM 57 185100
Disease Ontology 12 DOID:540
ICD9CM 35 378.7
MeSH 44 D013285
MedGen 42 C1861449

Summaries for Strabismus

OMIM : 57 Strabismus, a misalignment of the eyes also referred to as 'squint,' is one of the most common ocular disorders in humans, affecting 1 to 4% of the population. It is frequently associated with amblyopia (uniocular visual neglect) (Parikh et al., 2003). Strabismus is also a feature of several syndromes, including congenital fibrosis of extraocular muscles (see, e.g., CFEOM1; 135700), Duane retraction syndrome (126800), and chronic progressive external ophthalmoplegia with myopathy (530000). (185100)

MalaCards based summary : Strabismus, also known as strabismus, susceptibility to, 1, is related to esotropia and exotropia, and has symptoms including ophthalmoplegia, spasm of conjugate gaze and anomalies of divergence. An important gene associated with Strabismus is NALCN (Sodium Leak Channel, Non-Selective). The drugs Sevoflurane and Propofol have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are microtropia and behavior/neurological

Wikipedia : 76 Strabismus, also known as crossed eyes, is a condition in which the eyes do not properly align with each... more...

Related Diseases for Strabismus

Diseases related to Strabismus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 esotropia 33.3 TUBB3 SOBP CHN1 ADAT3
2 exotropia 33.2 TUBB3 CHN1
3 hypertropia 32.4 TUBB3 FGFR2 CHN1
4 amblyopia 32.3 TUBB3 SOBP GALC CHN1
5 hypotropia 31.7 TUBB3 CHN1
6 ocular motility disease 31.5 VANGL2 TUBB3 GPR143 CHN1
7 marcus gunn phenomenon 31.4 TUBB3 CHN1
8 pathologic nystagmus 30.5 TYR TUBB3 GPR143 GNB1 GALC
9 congenital ptosis 30.3 TUBB3 CHN1
10 congenital nystagmus 30.3 TYR TUBB3 GPR143
11 hypertelorism 29.8 POGZ MED13L FGFR2
12 alacrima, achalasia, and mental retardation syndrome 29.6 MPP4 MED13L GNB1 DHX30
13 mental retardation, anterior maxillary protrusion, and strabismus 12.4
14 mechanical strabismus 12.4
15 hemifacial hyperplasia with strabismus 12.3
16 ptosis, strabismus, and ectopic pupils 12.3
17 speech development, delayed, with facial asymmetry, strabismus, and transverse earlobe crease 12.1
18 ptosis strabismus diastasis 12.0
19 severe intellectual disability-hypotonia-strabismus-coarse face-planovalgus syndrome 12.0
20 paralytic squint 12.0
21 mehes syndrome 11.7
22 white-sutton syndrome 11.5
23 fourth cranial nerve palsy, familial congenital 11.4
24 tukel syndrome 11.4
25 abducens nerve disease 11.3
26 crouzon syndrome 11.3
27 mental retardation, autosomal recessive 36 11.3
28 fibrosis of extraocular muscles, congenital, 2 11.3
29 retinoblastoma 11.3
30 fibrosis of extraocular muscles, congenital, 1 11.2
31 brown syndrome 11.2
32 duane retraction syndrome 1 11.1
33 farsightedness 11.1
34 krauss herman holmes syndrome 11.1
35 oculocutaneous albinism 11.1
36 congenital toxoplasmosis 11.1
37 cyclotropia 11.1
38 fetal thalidomide syndrome 11.1
39 arthrogryposis, distal, type 5 11.0
40 x-linked congenital stationary night blindness 11.0
41 naegeli-franceschetti-jadassohn syndrome 10.9
42 mental retardation, autosomal dominant 18 10.9
43 hypotonia, infantile, with psychomotor retardation 10.9
44 mental retardation, autosomal recessive 55 10.9
45 3mc syndrome 10.9
46 gatad2b-associated neurodevelopmental disorder 10.9
47 mcpherson robertson cammarano syndrome 10.9
48 microdontia hypodontia short stature 10.9
49 singh chhaparwal dhanda syndrome 10.9
50 albinism, oculocutaneous, type vi 10.9

Graphical network of the top 20 diseases related to Strabismus:



Diseases related to Strabismus

Symptoms & Phenotypes for Strabismus

Symptoms via clinical synopsis from OMIM:

57
Eyes:
strabismus
microtropia
cyclic strabismus (periodic esotrophia)


Clinical features from OMIM:

185100

Human phenotypes related to Strabismus:

32
# Description HPO Frequency HPO Source Accession
1 microtropia 32 HP:0031724

UMLS symptoms related to Strabismus:


ophthalmoplegia, spasm of conjugate gaze, anomalies of divergence

MGI Mouse Phenotypes related to Strabismus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 ADGRG1 CHN1 FGFR2 GALC GNB1 NALCN
2 cellular MP:0005384 9.7 ADGRG1 CHN1 FGFR2 GALC GNB1 MPP4
3 nervous system MP:0003631 9.5 ADGRG1 CHN1 DHX30 FGFR2 GALC GNB1

Drugs & Therapeutics for Strabismus

Drugs for Strabismus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
2
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 2078-54-8 4943
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable 1177-87-3
6
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
7
Povidone Approved Phase 4,Not Applicable 9003-39-8
8
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
9
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
10
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
11
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
12
Rimexolone Approved Phase 4 49697-38-3 39507
13
Acetylcholine Approved Phase 4,Phase 3,Not Applicable 51-84-3 187
14
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
15
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
16 tannic acid Approved Phase 4,Not Applicable
17
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
18
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
19
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
20
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
25 Platelet Aggregation Inhibitors Phase 4,Not Applicable
26 Anesthetics, Intravenous Phase 4,Phase 2,Not Applicable
27 Hypnotics and Sedatives Phase 4,Phase 2,Not Applicable
28 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
29 Anesthetics, Inhalation Phase 4,Not Applicable
30 Anesthetics, General Phase 4,Phase 2,Not Applicable
31 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
32 Anti-Infective Agents, Local Phase 4,Not Applicable
33 Chlorhexidine gluconate Phase 4
34 Disinfectants Phase 4
35 Anti-Infective Agents Phase 4,Not Applicable
36 Adrenergic Agents Phase 4,Not Applicable
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Analgesics Phase 4,Phase 1,Phase 2,Not Applicable
39 Pharmaceutical Solutions Phase 4,Not Applicable
40 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Ophthalmic Solutions Phase 4,Not Applicable
43 Hormone Antagonists Phase 4,Not Applicable
44 BB 1101 Phase 4,Not Applicable
45 Hormones Phase 4,Not Applicable
46 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
47 Autonomic Agents Phase 4,Phase 3,Not Applicable
48 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Not Applicable
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
50 Antiemetics Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 172)
# Name Status NCT ID Phase Drugs
1 Propofol for Treatment on Emergence Agitation Unknown status NCT02738814 Phase 4 propofol
2 Comparison of Intra Ocular Pressure After Insertion of the LMA Supreme and LMA Proseal in Pediatric Patients Unknown status NCT02508181 Phase 4
3 Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery Completed NCT01901588 Phase 4 Dexmedetomidine
4 The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia. Completed NCT03349515 Phase 4 Provodine-Iodine Solution;Group B will receive three drops in each eye of ophthalmic balanced salt solution.
5 Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery Completed NCT02816905 Phase 4 0.1 % Dexamethasone;0.1% Fluorometholone;1% Rimexolone
6 Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone Completed NCT01460355 Phase 4 Botulinum Toxin Type A;saline solution
7 The Effect of Anaesthesia Depth on Oculo-cardiac Reflex Completed NCT02379546 Phase 4 Desflurane
8 Povidone-iodine Antisepsis for Strabismus Surgery Completed NCT00461656 Phase 4 Preoperative conjunctival irrigation with 5% or 1.25% PI
9 Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children Completed NCT01895023 Phase 4 Dexmedetomidine;Midazolam;Saline
10 Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients Completed NCT02072083 Phase 4 Dexmedetomidine;Ketamine
11 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
12 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
13 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
14 Vision In Preschoolers Study (VIP Study) Unknown status NCT00038753 Phase 3
15 A Trial of Bifocals in Myopic Children With Esophoria Unknown status NCT00000128 Phase 3
16 Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus Completed NCT01584843 Phase 3 GSK1358820
17 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
18 The Prism Adaptation Study (PAS) Completed NCT00000121 Phase 3
19 Amblyopia (Lazy Eye) Treatment Study Completed NCT00001864 Phase 3 Atropine
20 Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed NCT00000170 Phase 3 Atropine
21 Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children Completed NCT00091923 Phase 3
22 Orthoptic Changes Following Photorefractive Keratectomy Completed NCT01279993 Phase 3
23 Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds Completed NCT00315328 Phase 3 Atropine
24 Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children Completed NCT00525174 Phase 3
25 Botox Instead of Strabismus Surgery (BISS) Recruiting NCT03459092 Phase 3 Botulinum toxin type A
26 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
27 The Effect of Slanted Recession of Horizontal Muscle on Horizontal Strabismus With Abnormal Accommodative Convergence /Accommodation Ratio (AC/A) Recruiting NCT03555045 Phase 2, Phase 3
28 Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia Active, not recruiting NCT02371460 Phase 3
29 Comparison of Medial Rectus Resection and Plication in Exotropic Patients Not yet recruiting NCT03768362 Phase 2, Phase 3
30 Human Milk Fortification in Extremely Preterm Infants Not yet recruiting NCT03797157 Phase 2, Phase 3
31 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
32 Prevention of Complications of Eye Surgery Completed NCT00478907 Phase 2 KETAMINE, PROPOFOL, THIOPENTAL
33 Eye Muscle Surgery to Treat Congenital Nystagmus Completed NCT00001866 Phase 2
34 Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease Completed NCT02023866 Phase 2 Cysteamine Bitartrate
35 Grading Versus Classic Inferior Oblique Anterior Transposition in Patient With Asymmetric Dissociated Vertical Deviation Recruiting NCT03135938 Phase 1, Phase 2
36 Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome Recruiting NCT03717909 Phase 2 Sodium Valproate 200Mg E/C Tablet;Sodium Valproate matched placebo
37 Effect of Intravenous Nalbuphine on Emergence Agitation Not yet recruiting NCT03470077 Phase 2 IV nalbuphine 0.1 mg/kg with induction of anesthesia.;IV nalbuphine 0.1 mg/kg at the end of surgery.
38 Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia Terminated NCT01267500 Phase 2
39 A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Terminated NCT02473445 Phase 2 Cysteamine Bitartrate
40 The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients Unknown status NCT00917982 Phase 1
41 Monovision for the Treatment of Diplopia Completed NCT01426672 Phase 1
42 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery Completed NCT00344201 Phase 1
43 Visual Cortex Stimulation in Patients With Amblyopia Completed NCT00097162 Phase 1
44 Dichoptic Virtual Reality Therapy for Amblyopia in Adults Terminated NCT02246556 Phase 1
45 Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia Unknown status NCT02152787 Not Applicable Injection of propofol 1.0mg/kg;propofol 0.5mg/kg;normal saline
46 Pain Medications in Children Undergoing Strabismus Surgery Unknown status NCT02789969 Not Applicable Hydromorphone;Fentanyl
47 Dexamethasone (Sterodex) Versus Loteprendol (Lotemax) Eye Drops Following Strabismus Surgery Unknown status NCT02825186 Not Applicable Loteprendol etabonate 0.5%;Dexamethasone 0.1%
48 The Use of Interactive Binocular Treatment (I-BiT) for the Management of Anisometropic, Strabismic and Mixed Amblyopia in Children Aged 3.5 - 12 Years Unknown status NCT02810847 Not Applicable
49 The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium Unknown status NCT02108795 Not Applicable Remifentanil;Placebo
50 Surgery for Esotropia Under Topical Anesthesia Unknown status NCT00993174 Not Applicable

Search NIH Clinical Center for Strabismus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: strabismus

Genetic Tests for Strabismus

Genetic tests related to Strabismus:

# Genetic test Affiliating Genes
1 Susceptibility to Strabismus 29
2 Strabismus 29

Anatomical Context for Strabismus

MalaCards organs/tissues related to Strabismus:

41
Eye, Testes, Thyroid, Cortex, Brain, Bone, Myeloid

Publications for Strabismus

Articles related to Strabismus:

(show top 50) (show all 1509)
# Title Authors Year
1
Accommodative Esotropia Treatment Plan Utilizing Simultaneous Strabismus Surgery and Photorefractive Keratectomy. ( 29339065 )
2018
2
Binocular stereo acuity affects monocular three-dimensional shape perception in patients with strabismus. ( 29306865 )
2018
3
Position matching between the visual fields in strabismus. ( 29356815 )
2018
4
Effect of intravenous preoperative versus postoperative paracetamol on postoperative nausea and vomiting in patients undergoing strabismus surgery: A prospective randomized study. ( 29450877 )
2018
5
Strabismus Postoperative Instructions to Patients and Parents. ( 29796675 )
2018
6
Vergence and Strabismus in Neurodegenerative Disorders. ( 29867716 )
2018
7
Intramuscular Distribution of the Abducens Nerve in the Lateral Rectus Muscle for the Management of Strabismus. ( 29447480 )
2018
8
Clinical features of strabismus and nystagmus in bilateral congenital cataracts. ( 29862181 )
2018
9
Congenital Restrictive Strabismus. ( 29346468 )
2018
10
Our experience with strabismus surgery under topical anesthesia performed at a tertiary eye care center. ( 29380804 )
2018
11
Hypohidrotic ectodermal dysplasia with strabismus. ( 29573265 )
2018
12
The impact of strabismus surgery on gait pattern in patients with congenital or starting within one year of age strabismus. ( 29339174 )
2018
13
Amblyopia, Strabismus and Refractive Errors in Congenital Ptosis: a systematic review and meta-analysis. ( 29844360 )
2018
14
Dry eye disease in strabismus patients: Does eye deviation harm ocular surface? ( 29406988 )
2018
15
Adjustable Strabismus Surgery under Topical Anesthesia: Alignment in Supine vs Seated Position. ( 29313409 )
2018
16
The effect of amniotic membrane grafting on healing and wound strength after strabismus surgery in a rabbit model. ( 29225157 )
2018
17
One-Muscle Strabismus Surgery: A Review. ( 29913025 )
2018
18
Multiple-Choice Answer Form Completion Time in Children With Amblyopia and Strabismus. ( 29902312 )
2018
19
Sugammadex affects emergence agitation in children undergoing strabismus surgery. ( 29962259 )
2018
20
Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children. ( 29958057 )
2018
21
Endophthalmitis following Strabismus Surgery: IPOSC Global Study. ( 29966454 )
2018
22
Scleral dellen following strabismus surgery. ( 29848534 )
2018
23
Differentiating Acute and Subacute Vertical Strabismus Using Different Head Positions During the Upright-Supine Test. ( 29450486 )
2018
24
Transient ischemic attack characterized by external strabismus of the left eye: A case report. ( 29901646 )
2018
25
Botulinum toxin chemodenervation for childhood strabismus in England: National and local patterns of practice. ( 29902283 )
2018
26
Botulinum Toxin for the Treatment of Cyclic Strabismus in Children: Three Case Reports. ( 29452451 )
2018
27
Erratum for &amp;quot;Comparison of Minimally Invasive Strabismus (MISS) and Conventional Strabismus Surgery Using the Limbal Approach&amp;quot;. ( 29378080 )
2018
28
Strabismus surgery for diplopia in chronic progressive external ophthalmoplegia. ( 29582258 )
2018
29
Use of a Binocular Optical Coherence Tomography System to Evaluate Strabismus in Primary Position. ( 29852032 )
2018
30
Strabismus Recognition Using Eye-Tracking Data and Convolutional Neural Networks. ( 29854365 )
2018
31
The Effect of Botulinum Toxin Augmentation on Strabismus Surgery for Large-Angle InfantileA Esotropia. ( 29476725 )
2018
32
Congenital melanocytic naevus and congenital strabismus. ( 29808480 )
2018
33
Developing Binocular Optical Coherence Tomography for Strabismus: Not a Simple Task. ( 29852035 )
2018
34
Changes in conjunctival-scleral thickness after strabismus surgery measured with anterior segment optical coherence tomography. ( 29980870 )
2018
35
Endophthalmitis Following Pediatric Cataract Surgery: An International Pediatric Ophthalmology and Strabismus Council Global Perspective. ( 28991343 )
2018
36
Prevalence and risk factors of strabismus in children and adolescents in South Korea: Korea National Health and Nutrition Examination Survey, 2008-2011. ( 29444106 )
2018
37
Long-term follow-up of cryopreserved amniotic membrane transplant during strabismus reoperations: Up 85 months' follow-up. ( 29952631 )
2018
38
Altered spontaneous brain activity patterns in strabismus with amblyopia patients using amplitude of low-frequency fluctuation: a resting-state fMRI study. ( 30275692 )
2018
39
Postural stability and visual impairment: Assessing balance in children with strabismus and amblyopia. ( 30335817 )
2018
40
Patient-reported outcome measures in amblyopia and strabismus: a systematic review. ( 28636173 )
2018
41
Amblyopia and strabismus: trends in prevalence and risk factors among young adults in Israel. ( 28814414 )
2018
42
The Underestimated Role of Refractive Error (Hyperopia, Myopia, and Astigmatism) and Strabismus in Children With ADHD. ( 30371126 )
2018
43
Food and Drug Administration, American Academy of Ophthalmology, American Academy of Optometry, American Association for Pediatric Ophthalmology and Strabismus, American Optometric Association, American Society of Cataract and Refractive Surgery, and Contact Lens Association of Ophthalmologists Co-Sponsored Workshop: Controlling the Progression of Myopia: Contact Lenses and Future Medical Devices. ( 29923881 )
2018
44
Orbital cellulitis with choroidal detachment following strabismus surgery in an adult. ( 30171895 )
2018
45
Asymptomatic endophthalmitis following strabismus correction in a pediatric patient. ( 30233756 )
2018
46
Prevalence of Strabismus Among Children With Neurofibromatosis Type 1 Disease With and Without Optic Pathway Glioma. ( 30371910 )
2018
47
Deep lateral wall orbital decompression following strabismus surgery in patients with Type II ophthalmic Graves' disease. ( 29319400 )
2018
48
Ocular Surface Leiomyoma in a Child after Strabismus Repair. ( 30454719 )
2018
49
Management of graves myopathy: Understanding and managing vertical strabismus from thyroid eye disease. ( 30056089 )
2018
50
Simultaneous Versus Sequential Ptosis and Strabismus Surgery in Children. ( 28661930 )
2018

Variations for Strabismus

ClinVar genetic disease variations for Strabismus:

6 (show top 50) (show all 62)
# Gene Variation Type Significance SNP ID Assembly Location
1 TYR NM_000372.4(TYR): c.265T> C (p.Cys89Arg) single nucleotide variant Pathogenic rs28940877 GRCh37 Chromosome 11, 88911386: 88911386
2 TYR NM_000372.4(TYR): c.265T> C (p.Cys89Arg) single nucleotide variant Pathogenic rs28940877 GRCh38 Chromosome 11, 89178218: 89178218
3 DMBX1 NM_147192.2(DMBX1): c.367C> T (p.Arg123Trp) single nucleotide variant Likely pathogenic rs730882203 GRCh38 Chromosome 1, 46510953: 46510953
4 DMBX1 NM_147192.2(DMBX1): c.367C> T (p.Arg123Trp) single nucleotide variant Likely pathogenic rs730882203 GRCh37 Chromosome 1, 46976625: 46976625
5 SPART NM_001142294.1(SPART): c.1450dupA (p.Thr484Asnfs) duplication Likely pathogenic rs730882198 GRCh38 Chromosome 13, 36314260: 36314260
6 SPART NM_001142294.1(SPART): c.1450dupA (p.Thr484Asnfs) duplication Likely pathogenic rs730882198 GRCh37 Chromosome 13, 36888397: 36888397
7 NF1 NM_001042492.2(NF1): c.1987G> A (p.Gly663Arg) single nucleotide variant Uncertain significance rs140653372 GRCh37 Chromosome 17, 29552254: 29552254
8 NF1 NM_001042492.2(NF1): c.1987G> A (p.Gly663Arg) single nucleotide variant Uncertain significance rs140653372 GRCh38 Chromosome 17, 31225236: 31225236
9 STXBP1 NM_003165.3(STXBP1): c.364C> T (p.Arg122Ter) single nucleotide variant Pathogenic rs794727792 GRCh37 Chromosome 9, 130423419: 130423419
10 STXBP1 NM_003165.3(STXBP1): c.364C> T (p.Arg122Ter) single nucleotide variant Pathogenic rs794727792 GRCh38 Chromosome 9, 127661140: 127661140
11 PCDH19 NM_001184880.1(PCDH19): c.1091dupC (p.Tyr366Leufs) duplication Pathogenic rs758946412 GRCh37 Chromosome X, 99662505: 99662505
12 PCDH19 NM_001184880.1(PCDH19): c.1091dupC (p.Tyr366Leufs) duplication Pathogenic rs758946412 GRCh38 Chromosome X, 100407507: 100407507
13 GNB1 NM_002074.4(GNB1): c.239T> C (p.Ile80Thr) single nucleotide variant Pathogenic rs752746786 GRCh37 Chromosome 1, 1737942: 1737942
14 GNB1 NM_002074.4(GNB1): c.239T> C (p.Ile80Thr) single nucleotide variant Pathogenic rs752746786 GRCh38 Chromosome 1, 1806503: 1806503
15 MED13L t(12;19)(q24.21;q12) Translocation Pathogenic NCBI36 Chromosome 12, 114971734: 114971744
16 MED13L t(12;19)(q24.21;q12) Translocation Pathogenic NCBI36 Chromosome 19, 35769937: 35769968
17 NALCN NM_052867.3(NALCN): c.3390G> A (p.Pro1130=) single nucleotide variant Pathogenic rs869312873 GRCh37 Chromosome 13, 101742197: 101742197
18 NALCN NM_052867.3(NALCN): c.3390G> A (p.Pro1130=) single nucleotide variant Pathogenic rs869312873 GRCh38 Chromosome 13, 101089846: 101089846
19 GNB1 NM_002074.4(GNB1): c.284T> C (p.Leu95Pro) single nucleotide variant Pathogenic rs869312824 GRCh37 Chromosome 1, 1736004: 1736004
20 GNB1 NM_002074.4(GNB1): c.284T> C (p.Leu95Pro) single nucleotide variant Pathogenic rs869312824 GRCh38 Chromosome 1, 1804565: 1804565
21 GNB1 NM_002074.4(GNB1): c.233A> G (p.Lys78Arg) single nucleotide variant Pathogenic rs869312823 GRCh38 Chromosome 1, 1806509: 1806509
22 GNB1 NM_002074.4(GNB1): c.233A> G (p.Lys78Arg) single nucleotide variant Pathogenic rs869312823 GRCh37 Chromosome 1, 1737948: 1737948
23 GNB1 NM_002074.4(GNB1): c.228T> G (p.Asp76Glu) single nucleotide variant Pathogenic rs869312822 GRCh37 Chromosome 1, 1737953: 1737953
24 GNB1 NM_002074.4(GNB1): c.228T> G (p.Asp76Glu) single nucleotide variant Pathogenic rs869312822 GRCh38 Chromosome 1, 1806514: 1806514
25 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh37 Chromosome 12, 123001951: 123001951
26 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh38 Chromosome 12, 122517404: 122517404
27 FOXP1 NM_001244810.1(FOXP1): c.1396C> G (p.Pro466Ala) single nucleotide variant Likely pathogenic rs1057518926 GRCh38 Chromosome 3, 70977675: 70977675
28 FOXP1 NM_001244810.1(FOXP1): c.1396C> G (p.Pro466Ala) single nucleotide variant Likely pathogenic rs1057518926 GRCh37 Chromosome 3, 71026826: 71026826
29 SOX5 NM_006940.5(SOX5): c.482-2A> C single nucleotide variant Likely pathogenic rs1057518845 GRCh38 Chromosome 12, 23755726: 23755726
30 SOX5 NM_006940.5(SOX5): c.482-2A> C single nucleotide variant Likely pathogenic rs1057518845 GRCh37 Chromosome 12, 23908660: 23908660
31 GALC NM_000153.3(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 GRCh38 Chromosome 14, 87968393: 87968393
32 GALC NM_000153.3(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 GRCh37 Chromosome 14, 88434737: 88434737
33 GALC NM_000153.3(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 GRCh38 Chromosome 14, 87988523: 87988523
34 GALC NM_000153.3(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 GRCh37 Chromosome 14, 88454867: 88454867
35 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh37 Chromosome 15, 90193067: 90193067
36 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh38 Chromosome 15, 89649836: 89649836
37 SMARCA4 NM_001128849.1(SMARCA4): c.1358C> T (p.Thr453Ile) single nucleotide variant Likely benign rs1057518862 GRCh38 Chromosome 19, 10991262: 10991262
38 SMARCA4 NM_001128849.1(SMARCA4): c.1358C> T (p.Thr453Ile) single nucleotide variant Likely benign rs1057518862 GRCh37 Chromosome 19, 11101938: 11101938
39 MPP4 NM_033066.2(MPP4): c.946T> C (p.Trp316Arg) single nucleotide variant Pathogenic rs1057519443 GRCh37 Chromosome 2, 202539978: 202539978
40 MPP4 NM_033066.2(MPP4): c.946T> C (p.Trp316Arg) single nucleotide variant Pathogenic rs1057519443 GRCh38 Chromosome 2, 201675255: 201675255
41 DHX30 NM_138615.2(DHX30): c.1478G> A (p.Arg493His) single nucleotide variant Pathogenic rs1057519436 GRCh37 Chromosome 3, 47888040: 47888040
42 DHX30 NM_138615.2(DHX30): c.1478G> A (p.Arg493His) single nucleotide variant Pathogenic rs1057519436 GRCh38 Chromosome 3, 47846550: 47846550
43 DHX30 NM_138615.2(DHX30): c.1685A> G (p.His562Arg) single nucleotide variant Pathogenic rs1060499733 GRCh37 Chromosome 3, 47888247: 47888247
44 DHX30 NM_138615.2(DHX30): c.1685A> G (p.His562Arg) single nucleotide variant Pathogenic rs1060499733 GRCh38 Chromosome 3, 47846757: 47846757
45 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh37 Chromosome 1, 151378740: 151378740
46 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh38 Chromosome 1, 151406264: 151406264
47 TYR NM_000372.4(TYR): c.1352A> G (p.Tyr451Cys) single nucleotide variant Likely pathogenic rs376823382 GRCh38 Chromosome 11, 89284940: 89284940
48 TYR NM_000372.4(TYR): c.1352A> G (p.Tyr451Cys) single nucleotide variant Likely pathogenic rs376823382 GRCh37 Chromosome 11, 89018108: 89018108
49 MED13L NM_015335.4(MED13L): c.1971delT (p.Asp657Glufs) deletion Pathogenic GRCh38 Chromosome 12, 116008442: 116008442
50 MED13L NM_015335.4(MED13L): c.1971delT (p.Asp657Glufs) deletion Pathogenic GRCh37 Chromosome 12, 116446247: 116446247

Copy number variations for Strabismus from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 195555 5 152100000 155600000 Deletion AK124699 strabismus
2 195560 5 152100000 155600000 Deletion C5ORF21 strabismus
3 195565 5 152100000 155600000 Deletion C5ORF3 strabismus
4 195570 5 152100000 155600000 Deletion GALNT10 strabismus
5 195575 5 152100000 155600000 Deletion HAND1 strabismus
6 195580 5 152100000 155600000 Deletion MFAP3 strabismus
7 195585 5 152100000 155600000 Deletion NR2F1 strabismus
8 195590 5 152100000 155600000 Deletion SAP30L strabismus

Expression for Strabismus

Search GEO for disease gene expression data for Strabismus.

Pathways for Strabismus

GO Terms for Strabismus

Cellular components related to Strabismus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome membrane GO:0033162 8.62 GPR143 TYR

Biological processes related to Strabismus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membranous septum morphogenesis GO:0003149 8.96 FGFR2 VANGL2
2 eye pigment biosynthetic process GO:0006726 8.62 GPR143 TYR

Sources for Strabismus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....